CliffBio
biologic

Arexvy

Respiratory Syncytial Virus Vaccine, Adjuvanted

Loss of exclusivityMay 2035FDA regulatory exclusivity expiry
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameArexvy
Active ingredientRespiratory Syncytial Virus Vaccine, Adjuvanted
Strength120UG/.5ML
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalMay 2023
Marketing statusRx

More from GlaxoSmithKline Biologicals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Arexvy patent cliff — loss of exclusivity May 2035 | CliffBio